Edition:
United States

Immunovaccine Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

1.85CAD
25 Apr 2018
Change (% chg)

$0.05 (+2.78%)
Prev Close
$1.80
Open
$1.79
Day's High
$1.85
Day's Low
$1.79
Volume
48,950
Avg. Vol
108,115
52-wk High
$2.55
52-wk Low
$1.04

Latest Key Developments (Source: Significant Developments)

Immunovaccine Announces $12.5 Million Bought Deal Offering
Thursday, 25 Jan 2018 08:26am EST 

Jan 25 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES $12.5 MILLION BOUGHT DEAL OFFERING.IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Immunovaccine reports qtrly loss per share of ‍$0.02​
Thursday, 9 Nov 2017 05:05pm EST 

Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share ‍$0.02​.  Full Article

Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Wednesday, 8 Nov 2017 07:05am EST 

Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.  Full Article

Immunovaccine Q2 loss per share C$0.02
Tuesday, 8 Aug 2017 05:05pm EDT 

Aug 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces financial results for quarter ended June 30, 2017.Q2 basic loss per share c$0.02.  Full Article

Immunovaccine announces achievement in personalized cancer medicines
Wednesday, 12 Jul 2017 07:05am EDT 

July 12 (Reuters) - Immunovaccine Inc :Immunovaccine achieves breakthrough in support of developing personalized cancer immunotherapies.Immunovaccine Inc - ‍filed a patent application covering the novel DepoVax-based rapid formulation process​.  Full Article

Immunovaccine announces $10 million bought deal offering
Wednesday, 31 May 2017 08:46am EDT 

May 31 (Reuters) - Immunovaccine Inc ::Immunovaccine announces $10 million bought deal offering.Immunovaccine Inc says intends to use net proceeds of offering to advance company's various depovax™-based products clinical studies.Immunovaccine Inc - entered into a bought deal financing agreement to sell 7.7 million common shares of corporation at a price of $1.30 per common share.Immunovaccine Inc - offering is expected to close on or about June 21, 2017.  Full Article

Immunovaccine says to initiate mid-stage trial of its blood cancer drug
Tuesday, 16 May 2017 07:05am EDT 

May 16 (Reuters) - Immunovaccine Inc :Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug.Immunovaccine Inc says expects trial to begin enrolling patients following receipt of regulatory clearance from Health Canada.  Full Article

Immunovaccine net loss, comprehensive loss of $2.4 mln for quarter ended March 31
Wednesday, 10 May 2017 05:05pm EDT 

May 10 (Reuters) - Immunovaccine Inc ::Immunovaccine announces financial results for quarter ended March 31, 2017.Net loss and comprehensive loss of $2.4 million for quarter ended march 31, 2017, up $518,000.At March 31, 2017, immunovaccine had cash and cash equivalents of $11.8 million versus $13.5 million at Dec 31, 2016.  Full Article

Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate
Wednesday, 12 Apr 2017 07:05am EDT 

Immunovaccine Inc : Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate . Immunovaccine says 100 percent of healthy older adult volunteers who responded to vaccine achieved a sustained antigen-specific immune response .At one year, antibody levels measured were still at peak with no sign of decrease.  Full Article

BRIEF-Immunovaccine Announces $12.5 Million Bought Deal Offering

* IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE Source text for Eikon: Further company coverage: